The company has raised 1.2 million euros ($1.5 million) to advance its genomics platform, attracting investments from the online payment group Ogone and Foundation Life Sciences Partners, BioInform reported.
Belgian biopharma group UCB has partnered with IBM to provide physicians with a predictive tool for use in treating epileptic patients, and the company has worked on expanding its offerings after patents expired on its epilepsy drug Keppra.
Oxford University is marshaling money and scientists to explore massive datasets to uncover knowledge about diseases and treatments.
GlaxoSmithKline has been listening to parents' concerns about childhood vaccinations. Really listening. In fact, it has used big data analytics to sift through thousands of comments from Internet chat forums to try to get a better grasp of exactly what objections there are and how to best face them.
Martin Leach has spent the past several months building a new data sciences group at Biogen Idec, where his team of informatics and tech pros has undertaken the sizable task of enabling scientists and others at the biotech powerhouse to make use of Big Data.
Comprehend Systems and GNS Healthcare made progress with very different software tools for drug researchers. Yet both companies have lived up to FierceBiotech IT 's choice to include them in an October 2011 report on tech companies to watch in the biotech arena.
Sanofi research czar Elias Zerhouni has pushed for the company to delve deeply into the study of diseases before leaping into drug development. Now the French drug giant plans to collaborate with the software company NextBio to infuse patients' genomic and other data into its work on treatments for such diseases as cancer and diabetes.
Qiagen has purchased Ingenuity Systems for $105 million in cash. The Netherlands-based buyer plans to integrate the genomic database and analysis software from Ingenuity into its molecular diagnostics business. The buyout highlights the growing value of understanding the nuances of genomics to make precise diagnoses.
Life Technologies has found a new software partner for its bench top Ion PGM sequencer, one the jewels of the company crown that Thermo Fisher aims to grab in its $13.6 billion buyout of Life announced last week.
By Nick Paul Taylor The Fenwick & West analysis of life science venture capital investment in 2012 is a downbeat read. Equity investments dropped 19% and the number of first round financings fell...